[1]
|
Kim, J. and Feagins, L.A. (2020) Managing Patients with Inflammatory Bowel Disease Who Develop Prostate Cancer. Digestive Diseases and Sciences, 65, 22-30. https://doi.org/10.1007/s10620-019-05934-7
|
[2]
|
Mohammed, W., Hoskin, P., Henry, A., Gomez-Iturriaga, A., Robinson, A. and Nikapota, A. (2018) Short-Term Toxicity of High Dose Rate Brachytherapy in Prostate Cancer Patients with Inflammatory Bowel Disease. Clinical Oncology, 30, 534-538. https://doi.org/10.1016/j.clon.2018.06.007
|
[3]
|
Feagins, L.A., Kim, J., Chandrakumaran, A., Gandle, C., Naik, K.H., Cipher, D.J., et al. (2020) Rates of Adverse IBD-Related Outcomes for Patients With IBD and Concomitant Prostate Cancer Treated with Radiation Therapy. Inflammatory Bowel Diseases, 26, 728-733. https://doi.org/10.1093/ibd/izz175
|
[4]
|
Gestaut, M.M. and Swanson, G.P. (2017) Long Term Clinical Toxicity of Radiation Therapy in Prostate Cancer Patients with Inflammatory Bowel Disease. Reports of Practical Oncology & Radiotherapy, 22, 77-82.
https://doi.org/10.1016/j.rpor.2016.10.005
|
[5]
|
Litwin, M.S. and Tan, H.J. (2017) The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA, 317, 2532-2542.
|
[6]
|
Yao, P., Cui, M., Wang, H., Gao, H., Wang, L., Yang, T., et al. (2016) Quantitative Analysis of Intestinal Flora of Uygur and Han Ethnic Chinese Patients with Ulcerative Colitis. Gastroenterology Research and Practice, 2016, Article ID: 9186232. https://doi.org/10.1155/2016/9186232
|
[7]
|
Khan, I., Ullah, N., Zha, L., Bai, Y.R., Khan, A., Zhao, T., et al. (2019) Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome. Pathogens, 8, 126.
https://doi.org/10.3390/pathogens8030126
|
[8]
|
Shen, Z.H., Zhu, C.X., Quan, Y.S., Yang, Z.Y., Wu, S., Luo, W.W., et al. (2018) Relationship between Intestinal Microbiota and Ulcerative Colitis: Mechanisms and Clinical Application of Probiotics and Fecal Microbiota Transplantation. World Journal of Gastroenterology, 24, 5-14. http://dx.doi.org/10.3748/wjg.v24.i1.5
|
[9]
|
Schroeder, B.O. (2019) Fight Them or Feed Them: How the Intestinal Mucus Layer Manages the Gut Microbiota. Gastroenterology Report, 7, 3-12. https://doi.org/10.1093/gastro/goy052
|
[10]
|
Flier, S.N., Tanjore, H., Kokkotou, E.G., Sugimoto, H., Zeisberg, M. and Kalluri, R. (2010) Identification of Epithelial to Mesenchymal Transition as a Novel Source of Fibroblasts in Intestinal Fibrosis. The Journal of Biological Chemistry, 285, 20202-20212. https://doi.org/10.1074/jbc.M110.102012
|
[11]
|
Burns, J.A., Weiner, A.B., Catalona, W.J., Li, E.V., Schaeffer, E.M., Hanauer, S.B., et al. (2019) Inflammatory Bowel Disease and the Risk of Prostate Cancer. European Urology, 75, 846-852. https://doi.org/10.1016/j.eururo.2018.11.039
|
[12]
|
Mosher, C.A., Brown, G.R., Weideman, R.A., Crook, T.W., Cipher, D.J., Spechler, S.J., et al. (2018) Incidence of Colorectal Cancer and Extracolonic Cancers in Veteran Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 24, 617-623. https://doi.org/10.1093/ibd/izx046
|
[13]
|
So, J., Tang, W., Leung, W.K., Li, M., Lo, F.H., Wong, M.T.L., et al. (2017) Cancer Risk in 2621 Chinese Patients with Inflammatory Bowel Disease: A Population-Based Cohort Study. Inflammatory Bowel Diseases, 23, 2061-2068.
https://doi.org/10.1097/MIB.0000000000001240
|
[14]
|
Sfanos, K.S., Yegnasubramanian, S., Nelson, W.G. and De Marzo, A.M. (2018) The Inflammatory Microenvironment and Microbiome in Prostate Cancer Development. Nature Reviews Urology, 15, 11-24.
https://doi.org/10.1038/nrurol.2017.167
|
[15]
|
Annede, P., Seisen, T., Klotz, C., Mazeron, R., Maroun, P., Petit, C., et al. (2017) Inflammatory Bowel Diseases Activity in Patients Undergoing Pelvic Radiation Therapy. Journal of Gastrointestinal Oncology, 8, 173-179.
https://doi.org/10.21037/jgo.2017.01.13
|
[16]
|
Fijak, M. and Meinhardt, A. (2006) The Testis in Immune Privilege. Immunological Reviews, 213, 66-81.
https://doi.org/10.1111/j.1600-065X.2006.00438.x
|
[17]
|
Hughes, G.C. and Choubey, D. (2014) Modulation of Autoimmune Rheumatic Diseases by Oestrogen and Progesterone. Nature Reviews Rheumatology, 10, 740-751. https://doi.org/10.1038/nrrheum.2014.144
|
[18]
|
Quintero, O.L., Amador-Patarroyo, M.J., Montoya-Ortiz, G., Rojas-Villarraga, A. and Anaya, J.-M. (2012) Autoimmune Disease and Gender: Plausible Mechanisms for the Female Predominance of Autoimmunity. Journal of Autoimmunity, 38, J109-J119. https://doi.org/10.1016/j.jaut.2011.10.003
|
[19]
|
Beeson, P.B. (1994) Age and Sex Associations of 40 Autoimmune Diseases. The American Journal of Medicine, 96, 457-462. https://doi.org/10.1016/0002-9343(94)90173-2
|
[20]
|
Khalili, H., Higuchi, L.M., Ananthakrishnan, A.N., Richter, J.M., Feskanich, D., Fuchs, C.S., et al. (2013) Oral Contraceptives, Reproductive Factors and Risk of Inflammatory Bowel Disease. Gut, 62, 1153-1159.
http://dx.doi.org/10.1136/gutjnl-2012-302362
|